ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Ubiquitination of ACSL4 by Parkin Suppresses Ferroptosis and Rescues Glucocorticoid-Induced Bone Loss.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
Long-term glucocorticoids (GCs) use induces glucocorticoids-induced osteoporosis (GIOP), but the underlying mechanisms remain unclear. This study investigated the role of Parkin in regulating ACSL4-mediated ferroptosis in GIOP and developed a bone-targeted mRNA therapeutic strategy. Using dexamethasone (DEX)-treated bone marrow mesenchymal stem cells (BMSCs) and a GIOP mouse model, we found that GCs induced typical ferroptosis in BMSCs. Parkin expression was significantly downregulated in GIOP models. Parkin knockdown exacerbated DEX-induced lipid peroxidation, iron accumulation, and mitochondrial dysfunction, while inhibiting osteogenesis and promoting adipogenesis; Parkin overexpression reversed these phenotypes. Mechanistically, Parkin directly bound to ACSL4 and promoted its K48-linked polyubiquitination and proteasomal degradation. Based on these findings, we constructed DSS6-modified bone-targeted lipid nanoparticles (LNPs) (Parkin-LNP@DSS6), which efficiently encapsulated mRNA and exhibited excellent bone-homing ability. Parkin-LNP@DSS6 inhibited ferroptosis and restored osteogenic differentiation in vitro, and significantly improved bone microstructural parameters in GIOP mice. Transcriptome sequencing confirmed suppression of ferroptosis and fatty acid metabolism pathways. Collectively, this study reveals a novel mechanism by which Parkin inhibits BMSCs ferroptosis via K48 ubiquitination-mediated degradation of ACSL4 to alleviate GIOP, and provides a promising bone-targeted mRNA delivery strategy for GIOP and other ferroptosis-related bone diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.